Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Larimar Therapeutics (LRMR) EPS (Basic) (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed EPS (Basic) for 7 consecutive years, with -$1.42 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, EPS (Basic) fell 264.1% year-over-year to -$1.42, compared with a TTM value of -$3.8 through Dec 2019, down 94.87%, and an annual FY2024 reading of -$1.32, down 57.14% over the prior year.
  • EPS (Basic) was -$1.42 for Q4 2019 at Larimar Therapeutics, roughly flat from -$1.42 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.35 in Q1 2019 and bottomed at -$1.42 in Q3 2019.
  • Average EPS (Basic) over 5 years is -$0.63, with a median of -$0.55 recorded in 2016.
  • Peak annual rise in EPS (Basic) hit 91.42% in 2015, while the deepest fall reached 2733.33% in 2015.
  • Year by year, EPS (Basic) stood at -$0.85 in 2015, then surged by 55.29% to -$0.38 in 2016, then fell by 26.32% to -$0.48 in 2017, then increased by 18.75% to -$0.39 in 2018, then crashed by 264.1% to -$1.42 in 2019.
  • Business Quant data shows EPS (Basic) for LRMR at -$1.42 in Q4 2019, -$1.42 in Q3 2019, and -$0.61 in Q2 2019.